Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing new treatments for hematologic malignancies. It is advancing Tamibarotene, a selective RARa agonist, in Phase III and Phase II trials for higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML), respectively. Other assets include SY-2101 and SY-5609, with the latter being a potent CDK7 inhibitor for which the company is seeking out-licensing opportunities. The SYRS average annual return since 2016 is shown above.
The Average Annual Return on the SYRS average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SYRS average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SYRS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free SYRS Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
